A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novelwise Pharmaceutical Corporation
Tango Therapeutics, Inc.
Case Comprehensive Cancer Center
NaviFUS Corporation
Hoosier Cancer Research Network
Stemline Therapeutics, Inc.
Weill Medical College of Cornell University
University of Texas Southwestern Medical Center
Hoffmann-La Roche
Stanford University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center